NO962752L - Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose - Google Patents

Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose

Info

Publication number
NO962752L
NO962752L NO962752A NO962752A NO962752L NO 962752 L NO962752 L NO 962752L NO 962752 A NO962752 A NO 962752A NO 962752 A NO962752 A NO 962752A NO 962752 L NO962752 L NO 962752L
Authority
NO
Norway
Prior art keywords
bone loss
diaryl
osteoporosis
treatment
medicament
Prior art date
Application number
NO962752A
Other languages
English (en)
Norwegian (no)
Other versions
NO962752D0 (no
Inventor
Virender M Labroo
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of NO962752D0 publication Critical patent/NO962752D0/no
Publication of NO962752L publication Critical patent/NO962752L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO962752A 1993-12-30 1996-06-28 Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose NO962752L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/175,899 US5389646A (en) 1993-12-30 1993-12-30 Methods for treatment and prevention of bone loss using 2,3-benzopyrans
PCT/US1994/014568 WO1995017892A1 (en) 1993-12-30 1994-12-14 Use of 2,3-diaryl-1-benzopyran derivatives for the manufacture of a medicament in the treatment and prevention of bone loss and osteoporosis

Publications (2)

Publication Number Publication Date
NO962752D0 NO962752D0 (no) 1996-06-28
NO962752L true NO962752L (no) 1996-08-29

Family

ID=22642125

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962752A NO962752L (no) 1993-12-30 1996-06-28 Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose

Country Status (11)

Country Link
US (1) US5389646A (fi)
KR (1) KR100213963B1 (fi)
CN (1) CN1142767A (fi)
AU (1) AU701411B2 (fi)
CA (1) CA2180178C (fi)
CZ (1) CZ192396A3 (fi)
FI (1) FI962685A (fi)
HU (1) HUT75705A (fi)
NO (1) NO962752L (fi)
RU (1) RU2166316C2 (fi)
WO (1) WO1995017892A1 (fi)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease
US5637598A (en) * 1994-11-18 1997-06-10 Eli Lilly And Company Methods of inhibiting bone loss
BR9711805A (pt) * 1996-06-20 2002-01-15 Regents The Univesity Of Texas Compostos e métodos para providenciar preparações farmacologicamente ativas e uso dos mesmos
US6043269A (en) * 1996-10-28 2000-03-28 Novo Nordisk A/S cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US8080675B2 (en) * 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
NZ553834A (en) 2004-09-21 2010-03-26 Novogen Res Pty Ltd 7-hydroxy-3,4-diphenyl-chroman and chromene derivatives
EA022551B1 (ru) 2010-06-10 2016-01-29 Серагон Фармасьютикалс, Инк. Модуляторы рецепторов эстрогена и их применение
ES2773732T3 (es) 2010-11-01 2020-07-14 Mei Pharma Inc Composiciones de isoflavonoides y procedimientos para el tratamiento del cáncer
CA2857057A1 (en) 2011-12-14 2013-06-20 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
DK3253208T3 (da) 2015-02-02 2021-06-07 Mei Pharma Inc Kombinationsterapier til anvendelse i behandlingen af brystcancer
CN104926776B (zh) * 2015-07-06 2018-05-25 江南大学 4-苯甲酰亚甲基黄烷类衍生物的绿色合成方法
SG11201803119XA (en) 2015-10-27 2018-05-30 Sun Pharma Advanced Res Co Ltd Novel heterocyclic antiestrogens
PE20221588A1 (es) 2019-07-22 2022-10-10 Sun Pharma Advanced Res Co Ltd Degradador selectivo del receptor de estrogeno

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1518002C3 (de) * 1965-01-02 1975-01-23 Merck Patent Gmbh, 6100 Darmstadt Isoflavane und Isoflavene und Verfahren zu Ihrer Herstellung sowie diese enthaltende Arzneimittel
US4210644A (en) * 1978-02-23 1980-07-01 The Johns Hopkins University Male contraception
US4489056A (en) * 1982-06-30 1984-12-18 Merck & Co., Inc. Acid anhydrides as rate controlling agent for the erosion of polymers which latter polymers have beneficial substances dispersed throughout their matrix or where the polymer matrix surrounds the beneficial substance
JPS60132976A (ja) * 1983-12-21 1985-07-16 Takeda Chem Ind Ltd 新規３−フエニル−４ｈ−１−ベンゾピラン−４−オン誘導体
US4644012A (en) * 1983-12-21 1987-02-17 Takeda Chemical Industries, Ltd. Treatment for osteoporosis
US5254568A (en) * 1990-08-09 1993-10-19 Council Of Scientific & Industrial Research Benzopyrans as antiestrogenic agents
JP3502403B2 (ja) * 1991-12-16 2004-03-02 アベンティス ファーマ株式会社 骨吸収抑制剤
US5280040A (en) * 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives

Also Published As

Publication number Publication date
RU2166316C2 (ru) 2001-05-10
KR100213963B1 (en) 1999-08-02
HUT75705A (en) 1997-05-28
US5389646A (en) 1995-02-14
CZ192396A3 (en) 1997-03-12
NO962752D0 (no) 1996-06-28
CA2180178C (en) 2001-03-20
AU701411B2 (en) 1999-01-28
HU9601786D0 (en) 1996-09-30
FI962685A0 (fi) 1996-06-28
WO1995017892A1 (en) 1995-07-06
AU1403995A (en) 1995-07-17
CN1142767A (zh) 1997-02-12
FI962685A (fi) 1996-08-28
CA2180178A1 (en) 1995-07-06

Similar Documents

Publication Publication Date Title
DK0688214T3 (da) Fremgangsmåder til inhibering af knogletab med 3,4-diarylchroman
NO962752L (no) Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose
ATE215816T1 (de) Feste oral anzuwendende arzeneiform
DK0759757T3 (da) Orale, væskeformige alendronatformuleringer
GEP20043269B (en) Purine Derivatives, Method for Their Production and Composition Containing the Same
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
DK1623703T3 (da) Hydrocodonformuleringer med kontrolleret frigivelse
AP9400645A0 (en) Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release sold dosage forms of medicaments prepared thereby.
BG104620A (en) Oral pharmaceutical extended release dosage form
DK0833643T3 (da) Formuleringer af vandfrit mononatriumsalt af alendronat og deres anvendelse til behandling af knoglesygdomme
NO306894B1 (no) Anvendelse av galanthamin for fremstilling av en farmasöytisk formulering for behandling av nikotinavhengighet
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
DK0688215T3 (da) 3,4-diarylchromaner til behandling af dermatitis
NO912416D0 (no) Terapeutisk aktiv benzimidazolforbindelse og fremgangsmaate for dens fremstilling.
EP0302714A3 (en) Pharmaceutical composition for treatment of bone-wasting diseases
NO178336C (no) Analogifremgangsmåte for fremstilling av en terapeutisk aktiv benzimidazolforbindelse og mellomprodukter
WO2003099214A3 (en) Biguanide formulations
HUP0002905A2 (hu) 2-{4-[4-(4,5-Diklór-2-metilimidazol-1-il)butil]1-1piperazinil}-5-fluorpirimidin, előállítása és gyógyászati alkalmazása
MY114610A (en) Controlled drug delivery system for diltiazem.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application